Use this URL to cite or link to this record in EThOS: https://ethos.bl.uk/OrderDetails.do?uin=uk.bl.ethos.498505
Title: Pharmacological therapies for rhodopsin retinitis pigmentosa
Author: Mendes, Hugo Filipe Chaves Pereira
ISNI:       0000 0004 2674 3902
Awarding Body: University of London
Current Institution: University College London (University of London)
Date of Award: 2007
Availability of Full Text:
Access from EThOS:
Full text unavailable from EThOS. Please try the link below.
Access from Institution:
Abstract:
Mutations in the visual pigment protein rod opsin are the most common cause of autosomal dominant retinitis pigmentosa (ADRP) and the majority of these mutations lead to the misfolding of the protein. Patients with ADRP experience progressive loss of vision leading to blindness and at the moment no effective therapy is available. In this study I have developed a cellular model that can mimic the gain-of function and dominant-negative disease mechanisms in rhodopsin ADRP patients. Whereas wild-type rod opsin translocated to the plasma membrane of the cells, P23H mutant rod opsin misfolded was retained in the ER and accumulated in intracellular inclusions. Several pharmacological compounds were tested in this model. The retinoids 9-c/s-retinal and 11-c/s-retinal reduced inclusion incidence, alleviated cell death and promoted the translocation of the mutant protein to the plasma membrane in cells expressing P23H rod opsin. In cells co-expressing wild-type and P23H rod opsin these compounds restored the normal processing of the wild-type protein, indicating an alleviation of the dominant-negative mechanism of cell death. Chemical chaperones reduced inclusion incidence and cell death but, unlike retinoids, did not to promote the translocation of the mutant protein and did not alleviate the dominant-negative interaction between wild-type and P23H rod opsin. Heat shock protein inducers were also used. Some of these drugs reduced inclusion incidence and cell death in P23H cells. In addition, one partially promoted the translocation of the mutant protein and partially suppressed the dominant-negative mechanism of cell death induced by the mutant protein. Treatment with other compounds such as autophagy inducers also reduced inclusion incidence and cell death in cells expressing P23H rod opsin. These data have identified a range of compounds that demonstrate the 'proof of principle' that some of the gain of function and dominant-negative properties of mutant misfolded rod opsin can be manipulated. The efficacy of these compounds must be established in animal models prior to translation into the clinic.
Supervisor: Not available Sponsor: Not available
Qualification Name: Thesis (Ph.D.) Qualification Level: Doctoral
EThOS ID: uk.bl.ethos.498505  DOI: Not available
Share: